AU2002210415A1 - Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor - Google Patents

Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor

Info

Publication number
AU2002210415A1
AU2002210415A1 AU2002210415A AU1041502A AU2002210415A1 AU 2002210415 A1 AU2002210415 A1 AU 2002210415A1 AU 2002210415 A AU2002210415 A AU 2002210415A AU 1041502 A AU1041502 A AU 1041502A AU 2002210415 A1 AU2002210415 A1 AU 2002210415A1
Authority
AU
Australia
Prior art keywords
inhibitor
egfr antagonist
aromatase
antitumor combination
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002210415A
Inventor
Giorgio Massimini
Giovanni Minardi
Gabriella Piscitelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of AU2002210415A1 publication Critical patent/AU2002210415A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2002210415A 2000-07-18 2001-07-04 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor Abandoned AU2002210415A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0017635.4 2000-07-18
GBGB0017635.4A GB0017635D0 (en) 2000-07-18 2000-07-18 Antitumor combined therapy
PCT/EP2001/007676 WO2002005791A2 (en) 2000-07-18 2001-07-04 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor

Publications (1)

Publication Number Publication Date
AU2002210415A1 true AU2002210415A1 (en) 2002-01-30

Family

ID=9895895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002210415A Abandoned AU2002210415A1 (en) 2000-07-18 2001-07-04 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor

Country Status (6)

Country Link
US (1) US20050032759A1 (en)
EP (1) EP1315486A2 (en)
JP (1) JP2004503582A (en)
AU (1) AU2002210415A1 (en)
GB (1) GB0017635D0 (en)
WO (1) WO2002005791A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3351246T1 (en) 2001-02-19 2019-08-30 Novartis Pharma Ag Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
BRPI0414532B1 (en) 2003-09-19 2018-06-05 Astrazeneca Ab QUINAZOLIN DERIVATIVE COMPOUND, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION, AND USE OF A QUINAZOLIN DERIVATIVE COMPOUND
CN1898240B (en) * 2003-10-15 2011-08-03 Osi制药公司 Imidazopyrazine tyrosine kinase inhibitors
US8017321B2 (en) 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
CA2561950C (en) 2004-04-02 2010-04-20 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
EP1751309B1 (en) * 2004-05-27 2015-07-22 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
JP2008501654A (en) 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー Treatment with cisplatin and EGFR inhibitor
US20060148772A1 (en) * 2004-11-16 2006-07-06 Evans Astrid H Combination
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
BRPI0606542A8 (en) 2005-02-23 2018-03-20 Genentech Inc methods to increase the time to disease progression (ttp)
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
US7704129B2 (en) * 2005-07-12 2010-04-27 Tipper Tie, Inc. Ruckers capable of rucking fixed diameter coverings and associated devices, methods, systems and computer program products
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
KR20080101888A (en) * 2006-02-09 2008-11-21 다이이찌 산쿄 가부시키가이샤 Anti-cancer pharmaceutical composition
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
EP2584043A3 (en) * 2007-09-28 2013-10-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having improved kinetics in plasma
WO2009091939A1 (en) * 2008-01-18 2009-07-23 Osi Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
CL2009000647A1 (en) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject.
WO2009138780A2 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Therapeutic treatment - 355
ES2396613T3 (en) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopyrazines and substituted imidazotriazines
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
US20120121596A1 (en) 2009-03-20 2012-05-17 Germaine Fuh Bispecific anti-her antibodies
CN102405214A (en) 2009-04-20 2012-04-04 Osi药物有限责任公司 Preparation of c-pyrazine-methylamines
JP2012526138A (en) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー Use of OSI-906 to treat adrenocortical cancer
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
MY160556A (en) 2010-02-18 2017-03-15 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102068429B (en) * 2010-12-28 2011-12-14 西南大学 Application of fadrozole in inducing transformation of differentiated ovary of tilapia mossambica into functional testis and induction method thereof
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
BR112014003431A2 (en) 2011-08-17 2017-06-13 Genentech Inc antibody, nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, pharmaceutical agent, use of the antibody, method of treating an individual who has cancer, and time-lapse method for tumor recurrence
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
CN104271761B (en) 2011-11-30 2017-03-15 霍夫曼-拉罗奇有限公司 Erbb3 mutation in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (en) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Diagnosis and treatment of HER3 inhibitors
KR102291355B1 (en) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Identification of patients in need of pd-l1 inhibitor cotherapy
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
USD729294S1 (en) 2013-08-26 2015-05-12 Tipper Tie, Inc. Gripper for automated ruckers, reruckers, deruckers and/or skin brakes
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20040024044A1 (en) * 2000-09-08 2004-02-05 Di Salle Enrico Exemestane as chemopreventing agent

Also Published As

Publication number Publication date
JP2004503582A (en) 2004-02-05
GB0017635D0 (en) 2000-09-06
WO2002005791A3 (en) 2003-01-03
WO2002005791A2 (en) 2002-01-24
US20050032759A1 (en) 2005-02-10
EP1315486A2 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
AU2002210415A1 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2002358277A1 (en) Aerogel and metallic compositions
AU2001258771A1 (en) -secretase inhibitors
HK1061851A1 (en) Gyrase inhibitors and uses thereof
AU2002356762A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
AU2002255284A1 (en) Quinoline derivative having azolyl group and quinazoline derivative
AU2001240978A1 (en) Glycogen phosphorylase inhibitor
HK1053984B (en) Gyrase inhibitors and uses thereof
AU2002221047A1 (en) Quinazolinone derivatives
AU2001244302A1 (en) Assessment methods and systems
AU2002367773A1 (en) Fab i inhibitors
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2002320156A1 (en) Risk evaluation system and methods
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU2002302735A1 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
AU2002338989A1 (en) Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine derivatives
HUP0401162A3 (en) Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
AUPR647101A0 (en) An evaluation system and method therefor
AU6045801A (en) Inhibitor function check method and apparatus
AU2002354083A1 (en) Cylinder-lock and flat-key combination
WO2003020115A9 (en) Methods and compositions for the detection of cancer
AU2002259301A1 (en) Caspase inhibitors and uses thereof
AU2002223649A1 (en) Vegh inhibitors and their use